Abstract
The number of dialysis patients with chronic kidney disease (CKD) is gradually increasing, especially in Westernized countries. Renal fibrosis is a basic risk factor for CKD, and CKD in turn is considered to be an independent risk factor for cardiovascular disease. CKD is defined as a progressive loss of function over a long period of time. It affects patients worldwide and is associated with a high morbidity and mortality rate. CKD affects more than 13% of the population in the United States (USA) [1] and in Europe [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038–2047
Lameire N, Jager K, Van Biesen W et al (2005) Chronic kidney disease: a European perspective. Kidney Int 68(99):S30–S38
Vilayur E, Harris DC (2009) Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 5(7):375–383
Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGF-β, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106(11):1675–1680
Mangelsdorf DJ, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83(6):835–839
Kato S (1998) Transcriptional control by steroid receptor. Nippon Rinsho 56(7):1699–1704
Ito I, Hanyu A, Wayama M et al (2010) Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem 285(19):14747–14755
Willson TM (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43(4):527–550
Chevalier RL, Forbes MS, Thornhill BA (2009) Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75(11):1145–1152
Camp HS (2003) Thiazolidinediones in diabetes: current status and future outlook. Curr Opin Investig Drugs 4(4):406–411
Miyachi H (2007) Design, synthesis, and evaluation of characteristic subtype-selective peroxisome proliferator-activated receptor (PPAR) ligands. Curr Med Chem 14(22):2335–2343
Oyama T (2009) Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta Crystallogr D Biol Crystallogr 65(pt 8):786–795
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer
About this paper
Cite this paper
Miyachi, H. (2012). Nongenomic Mechanism-Mediated Renal Fibrosis-Decreasing Activity of a Series of PPAR-γ Agonists. In: Shibasaki, M., Iino, M., Osada, H. (eds) Chembiomolecular Science. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54038-0_25
Download citation
DOI: https://doi.org/10.1007/978-4-431-54038-0_25
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54037-3
Online ISBN: 978-4-431-54038-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)